Phoenix PharmaLabs Inc
Categories
Pharmaceuticals/Therapeutics
About
Phoenix has developed a novel class of poly-receptor morphinans with strong potential to replace the currently available opioid pain medicines that are euphoric, addictive and pose risk of death.
Membership Type
Industry Member
Contacts
Primary
Timmy Chou
Vice President, CFO
William Crossman
President & CEO
Bevelyn Jedynak
Government Affairs Contact
Powered By GrowthZone














